Mycophenolate mofetil (Cellcept)

Bibliography

• KOYAMA H, CECKA JM: Rejectionepisodes.In: ClinicalTransplants.Terasaki, Cecka (Eds.), UCLA Tissue Typing Laboratory, Los Angeles, CA (1992):391.
   Google Scholar
• KLIEM V, EBERHARD OK, OLDHAFER K et al.:FK506inthe treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infectiveprophylaxis.Transplant. Proc.(1996) 28:3166–3168.
   Google Scholar
• ALMOND PS, MATAS A, GILLINGHAM K et al:Riskfactorsfor chronic rejection in renal allograft recipients. Transplantation(1993) 55:752.
   PubMed Web of Science ®Google Scholar
• LINDHOLM A, OHLMAN S, ALBRECHTSEN D eta].:Theim-pact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal trans-plantstreatedby3cyclosporineregimens.Transplan-tation(1993) 56:307.
   Google Scholar
• ALLISON AC, EUGUI EM: Mycophenolatemofetil,ara-tionallydesignedimmunosuppressivedrug.Clin. Transplant.(1993) 7:96.
   Web of Science ®Google Scholar
• MORRIS RE, HOYT G, EUGUI EM, ALLISON AC: RS-61443is a novel purine synthesis inhibitor that prolongs al-lograft and xenograft survival and reverses acute re-jection.Meeting of the American College of Surgeons(1989). Abstract.
   Google Scholar
• PLATZ KP, SOLLINGER HW, HULLET DA et al.:RS-61443-anew,potentimmunosuppressiveagent.Transplanta-tion(1991) 51:27–31.
   PubMed Web of Science ®Google Scholar
• GIBLETT ER, ANDERSON JE, COHEN F, POLLARA B, MEU-WISSEN HJ: Adenosine-deaminasedeficiencyintwopa-tients with severely impaired cellular immunity. Lancet(1972) 2:1067–1069.
   PubMed Web of Science ®Google Scholar
• ALLISON AC, HOVI T, WATTS RW, WEBSTER AD: Immu-nological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthe-sisinlymphocytetransformation.Lancet(1975) 2:1179–1183.
   PubMed Web of Science ®Google Scholar
• ALLISON AC, EUGUI EM: Preferentialsuppressionoflymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil intransplantation.Transplant. Proc.(1994) 26:3205–3210.
   PubMed Web of Science ®Google Scholar
• SOLLINGER HW, EUGUI EM, ALLISON AC: RS-61443:mechanism of action, experimental and early clinical results.Clin. Transplant.(1991) 5:523.
   Web of Science ®Google Scholar
• NATSUMEDA Y, CARR SF: HumantypelandIIIMPdehy-drogenaseasdrugtargets.Ann. NY Acad. Sci.(1993) 696:88.
   PubMed Web of Science ®Google Scholar
• SOLLINGER HW, BELZER OF, DEIERHOI MH et al.:RS-61443 (mycophenolate mofetil): a multicenter study forrefractorykidneytransplantrejection.Am. Surg.(1993) 216:513.
   Google Scholar
• ALLISON AC, ALMQUIST SJ, MUELLER CD et al:Invitroimmunosuppressive effects of mycophenolic acid and anesterprodrug,RS-61443.Transplant. Proc.(1991) 23:10–14.
   PubMed Web of Science ®Google Scholar
• BURLINGHAM WJ, GRAILER AP, HULLETT DA et al.:Inhi-bitionofbothMLCandinvitroIgGmemoryresponsetotetanustoxoidbyRS-61443.Transplantation(1991) 51:545–547.
   PubMed Web of Science ®Google Scholar
• EUGUI EM, ALMQUIST SJ, MULLER CD et al.:Lymphocyte-selective cytostatic and immunosuppres-siveeffectsofmycophenolicacidinvitro:roleofde-oxyguanosinenucleotidedepletion.Scand. J. Immunol.(1991) 33:161–173.
   PubMed Web of Science ®Google Scholar
• GRAILER A, NICHOLS J, HULLET D et al.:Inhibitionofhu-man B cell responses in vitro by RS-61443, cyclospor-ineAandDAB48611-2.Transplant. Proc.(1991) 23:314–315.
   Google Scholar
• WEAVER JL, PINE PS, ASZALOS A: ComparisonoftheinvitroandbiophysicaleffectsofcyclosporineA,FK-506, and mycophenolic acid on human peripheral bloodlymphocytes.Immunopharmacol. Immunotoxicol.(1991) 13:563–576.
   PubMed Web of Science ®Google Scholar
• ZEEVI A, WOAN M, YAO GZ et al.:Comparativeinvitrostudies on the immunosuppressive activities of myco-phenolic acid, bredinin, FK 506, cyclosporine A, and rapamycin.Transplant. Proc.(1991) 23:2928–2930.
   Google Scholar
• SOKOLOSKI JA, SARTORELLI AC: Effectsoftheinhibi-tors of IMP dehydrogenase, tiazofurin and mycophe-nolicacid,onglycoproteinmetabolism.Mol. Pharmacol.(1985) 28:567–573.
   PubMed Web of Science ®Google Scholar
• LAURENT AF, DUMONT S, POINDRON P et al.:Inhibitionof mannosylation on human monocyte surface glyco-protein could explain some of the anti-inflammatory effectsofmycophenolatemofetil.Clin. Exp. Rheumatol.(1994) 11:110.
   Google Scholar
• KIGUCHI K, COLLART FR, HENNING-CHUBB C et al.:Celldifferentiation and altered IMP dehydrogenase ex-pression induced in human T-lymphblastoid leukemia cellsbymycophenolicacidandtiazofurin.Exp. Cell. Res.(1990) 187:47–53.
   PubMed Web of Science ®Google Scholar
• YU J, LEMAS V, PAGE T eta].:Inductionoferythroiddif-ferentiation in K562 cells by inhibitors of inosine monophosphatedehydrogenase.Cancer Res.(1989) 49:5555–5560.
   Google Scholar
• PLATZ KP, BECHSTEIN WO, ECKHOFF DE et al.:RS-61443reversesacuteallograftrejectionindogs.Surgery(1991) 110:736–741.
   PubMed Web of Science ®Google Scholar
• AZUMA H, BINDER J, HEEMAN U et al.:EffectsofRS-61443 on functional and morphological changes in chronicallyrejectingratkidneyallografts.Transplan-tation(1995) 59:460–466.
   PubMed Web of Science ®Google Scholar
• BECHSTEIN WO, SCHILLING M, STEELE DM et al.RS-61443/cyclosporine combination therapy prolongs canineliverallograftsurvival.Transplant. Proc.(1993) 25:702–703
   PubMed Web of Science ®Google Scholar
• MORRIS RE, WANG J: Comparisonoftheimmunosup-pressive effects of mycophenolic acid and the mor-pholinoethyl ester of mycophenolic acid (RS-61443) inrecipientsofheartallografts.Transplant. Proc.(1991) 23:493–496
   PubMed Web of Science ®Google Scholar
• MORRIS RE, HOYT EG, MURPHY MP et al.:Mycophenolicacid morpholinoethylester (RS-61443) is a new immu-nosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis.Transplant. Proc.(1990) 22:1659–1562.
   Google Scholar
• KAWAMURA T, HULLET DA, SUZUKI Y et al.:Enhance-ment of allograft survival by combination RS-61443 andDUP-785therapy.Transplantation(1993) 55:691–695.
   PubMed Web of Science ®Google Scholar
• TANABE M, TODO S, MURASE N et al.:Combinedimmu-nosuppressive therapy with low dose FK 506 and anti-metabolites in rat allogenic heart transplantation. Transplantation(1994) 58:23–27.
   PubMed Web of Science ®Google Scholar
• KNECHTLE SJ, WANG J, BURLINGHAM WJ et al.:Theinflu-ence of RS-61443 on antibody-mediated rejection. Transplantation(1992) 53:699–701.
   PubMed Web of Science ®Google Scholar
• MORRIS RE, WANG J, BLUM JR et al.:Immunosuppres-sive effects of the morpholinoethyl ester of mycophe-nolic acid (RS-61443) in rat and nonhuman primate recipientsofheartallografts.Transplant. Proc.(1991) 23:19–25.
   Google Scholar
• DALOZE P, CHEN H, QI S et al.:ProlongationofpancreasallograftsurvivalbyRS61443intherat.Int. Cong. New Immunosupp. Drugs.Montreal, Canada (1995) Abstract 27.
   Google Scholar
• COULOMBE M, HAO L, CALCINARO F eta].:Tolerancein-duction in adult animals: comparison of RS-61443 and anti-CD4treatment.Transplant. Proc.(1991) 23:31–32.
   Google Scholar
• HAO L, LAFFERTY KJ, ALLISON AC eta].:RS-61443allowsislet allografting and specific tolerance induction in adultmice.Transplant. Proc.(1990) 22:876–879.
   Google Scholar
• HAO L, CALCINARO F, LAFFERTY KJ et al.:Tolerancein-duction in adult mice: cyclosporine inhibits RS-61443-inducedtolerance.Transplant. Proc.(1991) 23:733–734.
   Google Scholar
• MURASE N, STARZL TE, DEMETRIS AJ et al.:Hamster-to-rat heart and liver xenotransplantation with FK506 plusantiproliferativedrugs.Transplantation(1993) 55:701–708.
   PubMed Web of Science ®Google Scholar
• HULLET DA, KAWAMURA T, FUJINO Y et al.:Prolonga-tion of allograft and xenograft survival with mycophe-nolate mofetil (RS-61443) and brequinar sodium (DUP-785).Transplant. Proc.(1993) 25:700–701.
   Google Scholar
• WANG J, MORRIS RE: Effectofsplenectomyandmono-or combination therapy with rapamycin, the morpho-linoethly1 ester of mycophenolic acid and deoxysper-gualinoncardiacxenograftsurvival.Transplant. Proc.(1991) 23:699–702.
   PubMed Web of Science ®Google Scholar
• OHAIR DP, MCMANUS RP, KOMOROWSKI R Inhibition of chronic vascular rejection in primate cardiac © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs(1998) 7(9) xenograftsusingmycophenolatemofetil.Ann. Thorac. Surg.(1994) 58:1311–1315.
   PubMed Web of Science ®Google Scholar
• SOLLINGER HW, DEIERHOI MH, BELZER FO et al.:RS-61443 - a Phase I clinical trial and pilot rescue study. Transplantation(1992) 53:428–432.
   PubMed Web of Science ®Google Scholar
• MycophenolateMofetil(RS-61443–000).Investigational Brochure (11th Edition).Syntex Research, Palo Alto, CA, USA (July 1996).
   Google Scholar
• LASKOW DA, DEIERHOI MH, HUDSON SL et al.:Theinci-dence of subsequent acute rejection following the treatment of refractory renal allograft rejection with mycophenolatemofetil(RS61443).Transplantation57:640.
   Google Scholar
• DEIERHOI MH, SOLLINGER HW, DIETHELM AG, BELZERFO, KAUFFMAN RS: One-yearfollow-upresultsofaPhase I trial of mycophenolate mofetil (RS61443) in ca-davericrenaltransplantation.Transplant. Proc.(1993) 25:693.
   PubMed Web of Science ®Google Scholar
• THE MYCOPHENOLATE MOFETIL RENAL REFRACTORY REJECTION STUDY GROUP: Mycophenolatemofetilforthe treatment of refractory, acute, cellular renal trans-plantrejection.Transplantation(1996) 61:722–729.
   PubMed Web of Science ®Google Scholar
• THE TRICONTINENTAL MYCOPHENOLATE MOFETIL RE-NAL TRANSPLANT TRIAL STUDY GROUP: Ablinded,ran-domized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation.Transplantation(1996) 61:1029–1037.
   PubMed Web of Science ®Google Scholar
• SOLLINGER HW FOR THE US RENAL TRANSPLANT MYCO-PHENOLATE MOFETIL STUDY GROUP: Mycophenolatemofetil for the prevention of acute rejection in pri-marycadavericrenalallograftrecipients.Transplanta-tion(1995) 60:225–232.
   PubMed Web of Science ®Google Scholar
• KLINTMALM GB, ASCHER NL, BUSUTTIL RW et al.:RS-61443 for treatment-resistant human liver rejection. Transplant. Proc.(1993) 25:679.
   PubMed Web of Science ®Google Scholar
• KIRKLIN JK, BOURGE RC, NAFTEL DC et al.:Treatmentfor recurrent heart rejection with mycophenolate mofetil(RS-61443):initialclinicalexperience.J. Heart Lung Transplant.(1994) 13:444–450.
   Google Scholar
• EUROPEAN MYCOPHENOLATE MOFETIL CO-OPERATIVESTUDY GROUP: Placebo-controlledstudyofmycophe-nolate mofetil combined with cyclosporin and corti-costeroidsforpreventionofacuterejection.Lancet(1995) 345:1321.
   PubMed Web of Science ®Google Scholar
• SOLEZ K, AXELSEN RA, BENEDIKTSSON H et al.:Interna-tional standardisation of criteria for the histologic di-agnosis of renal allograft rejection: the Banff working classificationofkidneytransplantpathology.Kidney Int.(1993) 44:411.
   PubMed Web of Science ®Google Scholar
• NEYLAN JF: Immunosuppressivetherapyinhigh-risktransplant patients. Dose-dependent efficacy of myco-phenolate mofetil in African-american renal allograft recipients.Transplantation(1997) 64:1277–1282.
   Google Scholar
• WOELLWARTH JV, BEHREND M, SCHLITT JH et al.:Anewimmunosuppressive protocol with high dose myco-phenolate mofetil for kidney transplantation in sensi-tizedpatients.Transplant. Proc.(In press.)
   Google Scholar
• THE MYCOPHENOLATE MOFETIL ACUTE RENAL REJEC-TION STUDY GROUP: Mycophenolatemofetilforthetreatment of a first acute renal allograft rejection. Transplantation(1998) 65:235–241.
   PubMed Web of Science ®Google Scholar
• WEIR MR, ANDERSON L, FINK JC et al.:Anovelapproachto the treatment of chronic allograft nephropathy. Transplantation(1997) 64:1706–1710.
   PubMed Web of Science ®Google Scholar
• GRINYO JM, GIL-VERNET S, SERON D et al.:Steroidwith-drawal in mycophenolate mofetil-treated renal allo-graftrecipients.Transplantation(1997) 63:1688–1690.
   Google Scholar
• BIRKELAND SA, LARSEN KE, ROHR N: Pediatricrenaltransplantationwithoutsteroids.Pediatr. Nephrol.(1998) 12:87–92.
   PubMed Web of Science ®Google Scholar
• FILLER G, EHRICH J: Mycophenolatemofetilforrescuetherapy in acute renal transplant rejection in children should always be monitored by measurement of troughconcentration.Nephrol. Dial. Transplant.(1997) 12:374–375.
   PubMed Web of Science ®Google Scholar
• GULANIKAR AC, MCDONALD AS, SUNGERTEKIN U, BELITSKY P: Theincidenceandimpactofearlyrejec-tions episodes on graft outcome in recipients of first cadaverkidneytransplants.Transplantation(1992) 53:232–328.
   Web of Science ®Google Scholar
• VANRENTERGHEM YFCH: Acuterejectionandrenalal-lograftoutcome.Nephrol. Dial. Transplant.(1994) 10:29–31.
   Web of Science ®Google Scholar
• MATHEW TH: Ablindedlong-termrandomizedmulti-center study of mycophenolate mofetil (MMF) in ca-daveric renal transplantation: results at 3 years. Transplantation(In press.)
   Google Scholar
• ALLISON AC, EUGUI EM: Preferentialsuppressionoflymphocyte proliferation by mycophenolate acid and predicted long-term effects of mycophenolate mofetil intransplantation.Transplant. Proc.(1994) 26:3205–3210.
   PubMed Web of Science ®Google Scholar
• O'HAIR DP, MCMANUS RP, KOMOROWSKI R: Inhibitionof chronic rejection in primate cardiac xenografts us-ingmycophenolatemofetil.Ann. Thorac. Surg.(1994) 58:1311–1313.
   PubMed Web of Science ®Google Scholar
• TAYLOR DO, ENSLEY RD, OLSEN SL, DUNN D, RENLUNDDG: Mycophenolatemofetil(RS-61443):preclinical,clinical, and three-year experience in heart transplan-tation.J. Heart Lung Transplant.(1994) 13:571–582.
   PubMed Web of Science ®Google Scholar
• RENLUND DG, GOPINATHAN SK, KFOURY AG, TAYLOR DO: Mycophenolatemofetil(MMF)inhearttransplan-tation:rejectionpreventionandtreatment.Clin. Trans-plant.(1996) 10:136–139.
   PubMed Web of Science ®Google Scholar
• MCDIARMID SV: Mycophenolatemofetilinlivertrans-plantation.Clin. Transplant.(1996) 10:140–145.
   PubMed Web of Science ®Google Scholar
• STEGALL MD, WACHS ME, EVERSON G et al.:Prednisonewithdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine andtacrolimus.Transplantation(1997) 64: 1755-1760.
   Google Scholar
• KLUPP J, BECHSTEIN WO, PLATZ KP et al.Mycopheno- late mofetil added to immunosuppression after liver © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs(1998) 7(9) transplantation-firstresults.TranspL Int.(1997) 10:223–228.
   Google Scholar
• CARR RR, YOSHIDA EM, CHUNG SW, PARTOVI N: Pri-mary induction with mycophenolate mofetil and cor-ticosteroids in a liver transplant recipient with hepatorenalsyndrome.Ann. Pharmacother.(1998) 32:45–48.
   PubMed Web of Science ®Google Scholar
• ECKHOFF DE, MCGUIRE BM, FRENETTE LR et al.:Tacro-limus (FK 506) and mycophenolate mofetil combina-tiontherapyversustacrolimusinadultlivertransplantation.Transplantation(1998) 65:180–187.
   PubMed Web of Science ®Google Scholar
• WHYTE RI, ROSSI SJ, MULLIGAN MS et al.:Mycopheno-late mofetil for obliterative bronchiolitis syndrome af-terlungtransplantation.Ann. Thoracic Surg.(1997) 64:945–948.
   PubMed Web of Science ®Google Scholar
• SPEICH R, BOEHLER A, THURNHEER R, WEDER W: Sal-vage therapy with mycophenolate mofetil for lung transplantbronchiolitisobliterans.Transplantation(1997) 64:533–535.
   PubMed Web of Science ®Google Scholar
• BRIFFA N, MORRIS RE: Newimmunosuppressiveregi-mensinlungtransplantation.Eur. Respir. J.(1997) 10:2630–2637.
   PubMed Web of Science ®Google Scholar
• BUSING M, MARTIN D, SCHULZ T et al.:Mycophenolatemofetil/tacrolimus/single-shotversusazathio-prine/cyclosporine/ATG in pancreas-kidney trans-plantation: results of a prospective randomized single-centerstudy.Transplant. Proc.(1998) 30:516–517.
   PubMed Web of Science ®Google Scholar
• SCHIFF MH, GOLDBLUM R, REES MMC: 2-Morpholino-ethyl mycophenolic acid (ME-MPA) in the treatment of refractoryrheumatoidarthritis(RA).Arthritis Rheum.(1990) 33:155.
   Google Scholar
• LAURENT AF, DUMONT S, POINDRON P, MULLER CD: My-cophenolic acid suppresses protein N-linked glycosy-lation in human monocytes and their adhesion to endothelialcellsandtosomesubstrates.Exp. Hematol.(1996) 24:59–67.
   PubMed Web of Science ®Google Scholar
• GOLDBLUM R: Therapyofrheumatoidarthritiswithmycophenolatemofetil.Clin. Exp. Rheumatol(1993) 11:117–119.
   PubMed Web of Science ®Google Scholar
• SCHIFF M: Emergingtreatmentsforrheumatoidarthri-tis.Am. J. Med.(1997) 102:11–15.
   Google Scholar
• STRAND V: Thefutureuseofbiologictherapiesincom-binationforthetreatmentofrheumatoidarthritis.J. Rheumatol.(1996) 44(Suppl.): 91–96.
   Web of Science ®Google Scholar
• BULLINGHAM R, SHAH J, GOLDBLUM R, SCHIFF M: Ef-fects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritispatients.Br. J. Clin. Pharmacol(1996) 41:513–516.
   PubMed Web of Science ®Google Scholar
• HOHENLEUTNER U, MOHR VU, MICHEL S, LANDTHALER M: Mycophenolatemofetilandcyclosporintreatmentforrecalcitrantpyodermagangrenosum.Lancet(1997) 350:1748.
   Google Scholar
• EPINETTE WW, PARKER CM, JONES EL, GREIST MC: Myco-phenolicacidforpsoriasis.J. Am. Acad. Dermatol(1987) 17:962–971.
   PubMed Web of Science ®Google Scholar
• BOHM M, BEISSERT S, SCHWARZ T, METZ D, LUGER T: Bullous pemphigoid treated with mycophenolate mof-etil.Lancet(1997) 349:541.
   PubMed Web of Science ®Google Scholar
• ENK AH, KNOP J: Treatmentforpemphigusvulgariswithmycophenolatemofetil.Lancet(1997) 350:494.
   PubMed Web of Science ®Google Scholar
• ZIMMER-MOLSBERGER B, KNAUF W, THIEL E: Mycophe-nolate mofetil for severe autoimmune haemolytic ane-mia.Lancet(1997) 350:1003.
   PubMed Web of Science ®Google Scholar
• HALLORAN P, MATHEW T, TOMLANOVICH S et al.:Myco-phenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Trans-plantStudyGroups.Transplantation(1997) 63:39–47.
   Google Scholar
• EUROPEAN MYCOPHENOLATE MOFETIL COOPERATIVE STUDY GROUP: MycophenolateMofetilinrenaltrans-plantation: 3-year results from the placebo-controlled trial.(Submitted.)
   Google Scholar
• O'GARA MJ, LEE CH, WEINBERG GA, NOTT JM, QUEENER SF: IMPdehydrogenasefromPneumocystiscariniiasapotentialdrugtarget.Antimicrob. Agents Chem other.(1997) 41:40.
   PubMed Web of Science ®Google Scholar
• BEHREND M, KOLDITZ M, KLIEM V et al.:Malignaciesinpatients under long-term immunosuppression after kidneytransplantation.Transplant. Proc.(1997) 29:834–835.
   PubMed Web of Science ®Google Scholar
• JACOBS F, MAMZER-BRUNEEL MF, SKHIRI H et al.:Safetyof the mycophenolate mofetil-allopurinol combina-tioninkidneytransplantrecipientswithgout.Trans-plantation(1997) 64:1087–1088.
   Google Scholar
• OPELZ G, HENDERSON R: Incidenceofnon-Hodgkinlymphoma in kidney and heart transplant recipients. Lancet(1993) 342:1514–1516.
   PubMed Web of Science ®Google Scholar
• HANTO DW, FRIZZERA G, GAJL-PECZALSKA KJ, SIMMONS RL: Epstein-Barrvirus,immunodeficiency,andBcelllymphoproliferations.Transplantation(1985) 39:461-472. Matthias Behrend
   Google Scholar